Paxman AB (publ) (PAX.ST) has a MoatMap StockRank of 45/100 based on Quality (56/100), Value (27/100), and Momentum (49/100) factor scores. The current signal is HOLD. A niche medical device company specializing in scalp cooling. While it has a respectable product, it lacks the scale, broad market liquidity, and powerful macro tailwinds required to make it a high-conviction compounder in our concentrated portfolio.
Paxman AB (publ) develops and markets the Paxman Scalp Cooling System, a medical device designed to prevent chemotherapy-induced hair loss. Paxman holds a strong competitive position as a specialized provider in the niche market of scalp cooling, backed by clinical evidence and regulatory approvals. It is a focused medical device company with a proprietary solution for a significant side effect of chemotherapy.
| Price | $5.63 |
| Market Cap | $140M |
| P/E (Forward) | 13.32 |
| Price/Book | 3.14 |
| Return on Equity | -3.3% |
| Return on Invested Capital | 1.3% |
| Debt/Equity | 1.12 |
| Gross Margin | 64.9% |
| Operating Margin | 0.2% |
| Revenue Growth | 30.7% |
| Free Cash Flow | $-179K |
Paxman AB (publ) operates in the Medical Devices industry, part of the Healthcare sector (Sweden).